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1. Introduction 
The epithelial to mesenchymal transition (EMT) is a highly coordinated process and a multi-
step event during which epithelial cells lose numerous epithelial characteristics and assume 
properties that are typical of mesenchymal cells, which requires complex changes in cell 
architecture and behavior. The conversion of epithelial cells to mesenchymal cells is critical 
for the formation of the body plan and in the differentiation of multiple tissues and organs 
during embryonic development and involves profound phenotypic changes such as the loss 
of cell-cell adhesion, the loss of cell polarity, and the acquisition of migratory and invasive 
properties (Thiery et al. 2009). EMT is also involved in the physiological response to injury 
and in the pathological processes such as organ fibrosis. Accumulating evidence suggests 
that aberrant activation of the EMT developmental program contributes to tumor initiation 
invasion, metastatic dissemination and acquisition of therapeutic resistance (Yang, et al., 
2004; Yang and Weinberg, 2008; Thiery et al., 2009; Singh and Settleman, 2010; Acloque et al., 
2009; Kalluri and Weinberg, 2009). EMT induction can participate in cancer initiation to 
promote the clonal expansion of premalignant epithelial cells (Tellez et al., 2011). Cancer 
cells undergoing EMT acquire the capacity to migrate, invade the stroma and metastasise. 
During the process of metastasis, the EMT program enables these cancer cells to disseminate 
from a primary tumor and also promotes their self-renewal capability to ensure generation 
of the critical tumor mass required for progression from micro- to macro-metastases (Ruan 
et al., 2009a; Ruan et al., 2009c; Ouyang et al., 2010). EMT-inducing signalling pathways, such 
as TGF-┚, Wnt, Notch and Hedgehog (Hh), along with other tumor microenvironmental 
cues, induce well-differentiated epithelial cells to convert into motile mesenchymal cells via 
the activation of multiple EMT transcription factors, including Twist1, Twist2, Snai1, Slug, 
ZEB1 and ZEB2. Similarities between developmental and oncogenic EMT have led to the 
identification of common contributing pathways, suggesting that the reactivation of 
developmental pathways in cancers contributes to tumor progression. For example, 
developmental EMT regulators including Twist1, Twist2, Snail, Slug and Six1, and Cripto, 
along with developmental signaling pathways including TGF-┚ and Wnt/┚-catenin, are 
misexpressed in breast cancer and correlate with poor clinical outcomes. 
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Evidence has recently been accumulating to support the hypothesis that tumors contain a 
subpopulation of tumor cells called cancer stem cells (CSCs), also known as tumor initiating 
cells or tumorigenic cells, which exhibit stem-like cell properties to self-renew, form tumor 
spheres, differentiate into heterogeneous populations of cancer cells, and seed new tumors 
in a xenotransplant system (Dontu et al., 2003; Gupta and Weinberg, 2009). In addition to 
initiating tumors, CSCs are thought to be capable of initiating metastasis. The CSC 
hypothesis provides an attractive model of tumor development and progression, holding 
that solid tumors are hierarchically organized and sustained by a small subset of the tumor 
cell population with stem cell properties. Under this hypothesis, sustained metastatic 
growth requires the dissemination of a CSC from the primary tumor followed by its re-
establishment in a secondary site. The CSC hypothesis has fundamental and important 
clinical implications, as the current development of cancer therapeutics is largely based on 
screening agents with the ability to cause bulk tumor regression in animal models or in 
clinical trials (Bao et al., 2006; Rich and Bao, 2007; Bao et al., 2008; Gupta and Weinberg, 
2009). Strategies aimed at efficiently targeting CSCs are critical for monitoring the progress 
of cancer treatment and for evaluating new therapeutic agents. The elucidation of signalling 
pathways which regulate CSC self-renewal and survival provides potential therapeutic 
targets. In addition, CSC behaviors are constantly regulated both by inside regulators such 
as transcription factors and external signals from their niches, including neighboring 
stromal, immune, and non-stem tumor cells. Targeting the neighboring non-stem cancer 
cells, stromal cells or the paracrine factors secreted by these cells may target CSCs indirectly, 
and thereby contribute to long-term remissions (Polyak and Hahn, 2006). 
Both the EMT and CSCs play a critical role in tumor metastasis, therapeutic resistance and 
recurrence; however, each alone can not explain the sum of the cellular events in tumor 
progression and the significance of EMT in regulating the stemness of CSCs remains 
unknown until very recently. Balancing these two concepts has led researchers to investigate 
a possible link between EMT and the CSC phenotype. Brabletz et al. (2005) proposed an 
integrated model–the migrating cancer stem cell concept that covers all aspects of human 
tumor progression. Mobile CSCs are located predominantly at the tumor-host interface and 
are derived from stationary CSCs through the acquisition of a transient EMT phenotype in 
addition to stemness. In a recent report, Mani et al. (2008) found that Twist1, Snai1 or TGF-β 
can transform nontumorigenic, immortalized human mammary epithelial cells (HMLEs) 
into mesenchymal-like cells and dedifferentiate HER2/neu-infected HMLE (HMLEN) cells 
into CD44highCD24low cancer stem-like cells via EMT. The resulting populations that have 
undergone an EMT and display mesenchymal morphology and stem cell markers can 
efficiently form mammospheres, soft agar colonies, and tumors. Moreover, other EMT 
inducers or regulators such as ZEB1, YB-1, LBX1 and Six1 have also been shown to induce 
well-differentiated cells and cancer cells to form populations with stem cell-like 
characteristics via promoting EMT, indicating that there is a crosstalk between the EMT 
program and the pathways involved in regulating stemness in stem cells (Mani et al., 2008; 
Morel et al., 2008; Evdokimova et al., 2009; Illopoulos et al., 2009; McCoy et al., 2009; Polyak 
and Weinberg, 2009; Wellner et al., 2009; Yu et al., 2009; Ouyang et al., 2010; Singh and 
Settleman, 2010). The critical roles of TGF-β, Wnt, Notch and other signaling pathways in 
promoting EMT and the stemness maintenance of stem cells adds to a growing body of 
evidence that cancer cells often reactivate latent developmental programs to regulate the 
multistep process in tumorigenesis. Furthermore, the expression of stemness and EMT 
markers in CSCs were associated with resistance to conventional anti-cancer therapies and 
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treatment failure, highlighting the urgency of improving tools for detecting and eliminating 
minimal residual disease. In this chapter, we focus on recent findings regarding the role of 
EMT signaling pathways in regulating the stemness of cancer stem cells. 
2. EMT signaling pathways in regulating stemness of CSCs  
During the EMT process, epithelial cells undergo specific series of events and dramatic 
phenotypic changes, lose expression of E-cadherin and other components of epithelial cell 
junctions, adopt a mesenchymal cell phenotype and acquire motility and invasive properties 
that allow them to migrate through the extracellular matrix. The functional loss of E-cadherin 
expression is considered a one of the hallmarks of EMT and a crucial event in the 
progression of papilloma into invasive carcinoma because the reduction of cell adhesion 
between cancer cells facilitates their ability to migrate individually and invade (Thiery et al., 
2009; Yilmaz and Christofori, 2009). E-cadherin promoter is repressed directly or indirectly 
by specific developmental transcription factors such as Twist1, Snai1, Slug, ZEB1, ZEB2, 
FOXC2, KLF8 and E47, which disrupts the polarity of epithelial cells and maintains a 
mesenchymal phenotype (Kang and Massague, 2004; Yang and Weinberg, 2008; Thiery et al., 
2009). Knockdown of E-cadherin by shRNA triggered EMT and resulted in acquisition of a 
mesenchymal phenotype and increased CSC activity in HMLER breast cancer cells (Gupta et 
al., 2009).  
2.1 EMT signaling from the microenvironment in regulating stemness of CSCs  
Tumor development is a continuous reciprocal interaction between tumor cells and their 
surrounding microenvironment, in which stromal cells and the extracellular matrix (ECM) 
play a decisive role in tumorigenesis (Bissell and Radisky, 2001; Hanahan and Weinberg, 
2011). Tumor microenvironment not only provides support for initiation and growth of the 
primary tumor, but also facilitates tumor metastatic dissemination to distant organ as an 
active participant. Tumor cells can only thrive in an aberrant microenvironment composed 
of altered ECM and various non-transformed neighbor cells. Cross-talk between cancer 
epithelial cells and their neighboring stromal cells is known to be critical to the growth and 
progression of tumors (Hanahan and Weinberg, 2000; Bissell and Radisky, 2001; Bhowmick 
et al., 2004; Bissell and Labarge, 2005; McAllister et al., 2008; Hanahan and Weinberg, 2011). 
In adult tissues, normal stem cells reside within highly defined anatomical niches that 
provide both cell-intrinsic and cell-extrinsic factors to maintain stem cells in undifferentiated 
states to self-renew or give rise to the full repertoire specialized cells in the tissues. Like their 
normal stem cells, CSCs have the ability both to self-renew and to differentiate to 
specialized cells with limited proliferation potential. Accumulating evidence has emerged 
that factors derived from the tumor microenvironment serve to regulate the stemness of 
CSCs. CSC niche can be considered as the tumor microenvironment surrounding CSCs that 
contributes to maintain the stemness of CSCs. CSCs may reside in and constantly affected by 
their aberrant niches, where cell-cell and cell-matrix interactions can provide unregulated 
external signals to support and maintain the undifferentiated phenotype of CSCs. CSCs may 
remain dormant in their aberrant niches until they are activated by the altered signals in the 
microenvironment. Recent work has begun to address the importance of the tumor 
microenvironment in regulating the EMT during tumorigenesis and also found that the 
emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor 
microenvironment components. 
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TGF-β signaling. TGF-β is a multifunctional cytokine that plays critical roles in tumor 
suppression and tumor progression, cell differentiation and tissue morphogenesis, and 
extracellular matrix production through activation of Smad and non-Smad signaling 
pathways. Current data show that TGF-┚ signaling pathway has a dual role in 
tumorigenesis as a tumor suppressor in early stage tumors or as a promoter of tumor 
progression and metastasis (Derynck et al., 2001; Massague, 2008). In the Smad-dependent 
pathway, TGF-┚ ligands bind to heterotetrameric complexes of receptors with serine-
threonine kinase activity leading to an increase in their ability to phosphorylate the receptor-
related Smad (R-Smad) proteins. The phosphorylated Smad2 and Smad3 then form 
heteromeric complexes with Smad4 and translocate into the nucleus to regulate the 
transcription of target genes. The amplitude and duration of Smad2/3-based signaling 
transpires through their physical interaction with a plethora of transcription factors, and 
with a variety of transcriptional co-activators and co-repressors in a gene- and cell-specific 
manner. Currently, TGF-β is recognized as a master regulator of EMT, during embryogenesis 
and tissue morphogenesis (i.e., type 1 EMT), wound healing and tissue fibrosis (i.e., type 2 
EMT), and tumor invasion and metastasis (i.e., type 3 EMT). Multiple transcription factors, 
including ZEB1, ZEB2, and Snai1, are induced by TGF-┚-Smad signaling and play important 
roles in TGF-┚-induced EMT. TGF-β employs HMGA2 (high-mobility group A2) to induce 
the expression of Twist1, Snai1 and Slug to promote EMT (Thuault et al., 2006). Non-Smad 
signaling activated by TGF-┚ also plays important roles in induction of EMT. Independent 
of Smad activity, TGFBR2 can directly phosphorylate the cell polarity protein, Par6, to 
promote the dissolution of cell junction complexes (Ozdamar et al., 2005; Thuault et al., 
2006). In addition, TGF-β signaling also cross-talks with other signaling pathways to act in 
concert to trigger EMT programs. Of these, Ras and Wnt signaling pathways synergize with 
TGF-┚ signaling, and play a critical role in the induction of EMT (Polyak and Weinberg, 
2009; Vincent et al., 2009). 
TGF-┚ family members and their signaling pathways also play a key role in the self-renewal 
and maintenance of stem cells in their undifferentiated state. A recent report about the role 
of TGF-β-induced EMT in human breast cancer demonstrated that the TGF-β pathway is 
specifically activated in CD44+ breast cancer cells (Shipitsin et al., 2007). The specific 
activation of TGF-┚ signaling in CD44+ breast cancer cells is due to the restricted expression 
of TGFBR2 in these cells and its epigenetic silencing in CD24+ cells. TGFBR inhibitor 
treatment specifically induces CD44+ cancer cells to undergo a mesenchymal-to-epithelial 
transition (MET) (Shipitsin et al., 2007). CD44high/CD24low cells isolated from HMLEs display 
a mesenchymal phenotype (Mani et al., 2008). After treatment with TGF-┚1, HMLEs adopt 
the CD44high/CD24low expression profile. The CD44high/CD24low subpopulations also 
display many characteristics of stem cells including self-renewal, tumorigenic and 
metastasis capability, and the ability to differentiate into myoepithelial or luminal epithelial 
cells. In addition, treatment of HMLER with TGF-β accelerates the emergence of 
CD44+CD24−/low cells from CD44lowCD24+ non-tumorigenic mammary epithelial cells via the 
activation of the Ras/MAPK signaling pathway (Morel et al., 2008). In MCF-10A cells, the 
knockdown of Akt1 promotes TGF-β-induced EMT and a stem cell-like phenotype 
(Iliopoulos et al., 2009). Recently, the activating transcription factor 3 (ATF3) is induced by 
TGF-┚ in the MCF10CA1a breast cancer cells and plays an integral role for TGF-┚ to 
upregulate its target genes Snail, Slug and Twist1, and to enhance cell motility. Interestingly, 
ATF3 increases the expression of the TGF-β itself, forming a positive-feedback loop for  
TGF-┚ signaling. Moreover, ectopic expression of ATF3 promotes EMT and increases 
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CD24low-CD44high population of cells, mammosphere formation and tumorigenesis (Yin et 
al., 2010).  
TGF-β may exert a similar effect on regulating the stem cell-like pool of other tumors. TGF-β 
is highly expressed in high-grade gliomas and upregulated TGF-β activity confers poor 
prognosis in glioma patients. TGF-┚ and LIF have been reported to induce the capacity to 
self-renew and prevent the differentiation of glioma-initiating cells (GICs) isolated from 
patient-derived glioma tissues (Penuelas et al., 2009). TGF-┚ increases GIC self-renewal 
through the Smad-dependent induction of LIF and the subsequent activation of the JAK-
STAT pathway. The induction of GIC self-renewal by TGF-β and LIF promotes 
tumorigenesis in vivo (Penuelas et al., 2009). TGF-β-FOXO signaling is shown to be essential 
in the maintenance of leukemia-initiating cells in chronic myeloid leukemia (CML) (Naka et 
al., 2010). 
Wnt signaling. Among many embryonic signaling pathways, Wnt pathway is one of critical 
pathways involved in regulating the stemness of CSCs and in the acquisition of EMT 
characterics during tumorigenesis. Wnt signals are transduced to the canonical pathway for 
cell fate determination, and to the noncanonical pathway for control of cell movement and 
tissue polarity. In the absence of active Wnt ligands, ┚-catenin is complexed with scaffold 
proteins Axin and APC, and phosphorylated by GSK-3┚ and CKI┙. Phosphorylated ┚-
catenin is then ubiquitinated and undergoes proteasome-mediated degradation. Canonical 
Wnt signals are transduced through membrane Frizzled (FZD) receptors and LRP5/LRP6 
co-receptor to the β-catenin signaling cascade. In the presence of active Wnt signaling, Wnt 
ligands bind to FZD and LRP, resulting in the phosphorylation of LRP6 by GSK-3┚ in its 
cytoplasmic region, leading to the recruitment of Dishevelled (Dvl) and Axin. ┚-catenin is 
then released from phosphorylation by GSK-3┚ and degradation by proteosome. The 
accumulated ┚-catenin translocates to the nucleus and regulates the expression of target 
genes. Noncanonical Wnt signals are transduced through FZD receptors and ROR2/RYK 
co-receptors to the Dishevelled-dependent or the Ca2+-dependent signaling cascades. The 
inappropriate expression of the Wnt ligand and Wnt binding proteins and the inappropriate 
activation of the Wnt signaling have been found in a variety of human cancers. In epithelial 
cells, ┚-catenin-E-cadherin complexes locate at adhesion junctions. Translocation of ┚-
catenin from adhesion junctions to the nucleus might result in the loss of E-cadherin and, 
subsequently, the EMT. Consistent with its role in embryonic development, many ┚-catenin 
target genes are involved in promoting stemness (Brabletz et al., 2005). Aberrant nuclear 
expression of β-catenin might confer cancer cells with these two capabilities, EMT and 
stemness, which promote malignant tumor progression. GSK-3β is an endogenous inhibitor 
of Snail and can phosphorylate Snai1. GSK-3β down-regulation by the FGF-dependent PI3-
K/Akt pathway directly results in the activation of the Snai1-EMT signaling cascade. 
Therefore, inhibition of GSK-3β function by Wnt and other pathways can promote Snai1 
stability and nuclear import to induce EMT (Zhou et al., 2004; Bachelder et al., 2005). In 
patients with a CML blast crisis, a ┚-catenin mutation may confer self-renewal properties on 
granulocyte-macrophage progenitors (Jamieson et al., 2004). In skin cancer, ┚-catenin 
signaling is essential to maintain the stemness properties of CSCs. Ablation of the ┚-catenin 
gene results in the loss of CSCs and a complete tumor regression (Reya and Clevers, 2005; 
Malanchi et al., 2008). Inhibiting of Wnt pathway through LRP6 decreases the ability of 
cancer cells to self-renew and seed tumors in vivo (DiMeo et al, 2009). Moreover, inhibition of 
Wnt signaling blocks tumor formation by promoting epithelial differentiation and 
repressing the EMT transcription factors, Twist1 and Slug. These data indicate that Wnt 
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pathway is involved in CSC self-renewal, EMT and metastasis in basal-like breast cancer 
(DiMeo et al, 2009). 
Notch signaling. Notch signaling is important for development and tissue homeostasis and 
regulates cell fate specification through local cell interactions in invertebrate and vertebrate 
organisms. For example, Notch activity promotes EMT during cardiac development via 
transcriptional induction of Snai1 and induces EMT in immortalized endothelial cells in vitro 
(Luika et al., 2004). Notch pathway is also activated in many human cancers and contributes 
to EMT and to cancer stem-like cell characteristics in tumorigenesis. Notch signaling 
pathway is essential for both nonneoplastic neural stem cells and embryonal brain tumors. 
The activation of Notch signaling is a hallmark of CD133+ CSCs in embryonal brain tumors, 
and blocking the Notch pathway by pharmacologic inhibitors of γ-secretase results in a 
depletion of CD133+ stem-like cells in these tumors (Fan et al., 2006). Notch signaling is 
associated with chemo-resistance and EMT phenotypes in gemcitabine-resistant pancreatic 
cancer cells (Wang et al., 2009). Recently, miR-200 members has been shown to target Notch 
pathway components, such as Jagged1 (Jag1) and the mastermind-like co-activators Maml2 
and Maml3, thereby mediating enhanced Notch activation by ZEB1 (Brabletz et al., 2011). 
Hedgehog signaling. As an ancient cell signaling system, the Hedgehog (Hh) signaling is an 
important developmental pathway. In the absence of Hh ligands Shh, Ihh or Dhh, Hh 
receptor Ptch inhibits a second transmembrane protein Smo. This repression is relived when 
Hh ligands bind to Ptch. Subsequently Smo causes activation of Hh pathway targets via the 
Gli family of transcription factors (Gli1, Gli2, and Gli3). Hh signaling is essential for 
embryonic pattern formation, hematopoiesis, and also plays an important role in 
tumorigenesis and stem cell maintenance (Trowbridge et al., 2006; Dierks et al., 2008; Zhao et 
al., 2009). Hh signaling components such as Ptch, Gli1, and Gli2 are highly expressed in 
normal and malignant human breast stem/progenitor cells. Activation of Hh signaling 
increases mammosphere-initiating cell number and mammosphere size, these effects are 
mediated by the polycomb gene, Bmi-1 (Liu et al., 2006). Hh signaling is also activated in 
Bcr-Abl-positive leukemic stem cells (LSCs) by the upregulation of Smo. Loss of Smo in Bcr-
Abl-positive hematopoiesis effectively inhibits the development of Bcr-Abl-positive 
leukemias in mice and abrogates the ability of the disease to re-transplant, indicating that 
the expansion of the Bcr-Abl-positive LSC pool is dependent on Hh signaling activation 
(Dierks et al., 2008). Another paper also revealed that the loss of Smo impairs hematopoietic 
stem cell renewal, lowers the propagation of Bcr-Abl-positive chronic myelogenous 
leukemia (CML), and decreases the growth of imatinib-resistant mouse and human CML 
(Zhao et al., 2009). However, a conditional Smo deletion or over-activation has no significant 
effects on adult HSC self-renewal and function, and the Hh signaling pathway is 
dispensable for adult HSC function (Gao et al., 2009). These results confirm recent findings 
that pharmacological Smo inhibition may only affect short-term repopulating HSCs in 
regular hematopoiesis; however, long-term repopulating HSCs and the long-term 
regeneration of hematopoiesis are not affected (Dierks et al., 2008). In addition, 
medulloblastomas arising from Patched-1-deficient or Patched-mutant mice contain CD15+ 
CSCs (Read et al., 2009; Ward et al., 2009). Hh/Wnt feedback is involved in regenerative 
proliferation of epithelial stem cells in bladder (Shin et al., 2011). A recent report directly 
demonstrated a key and essential role of Hh signaling in regulating the stemness of CSCs 
via EMT. Stem cells of human colon carcinomas at all stages acquire a high Hh-Gli signature 
coincident with the development of metastases. The growth of colon cancer xenografts, their 
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recurrence and metastases require active Hh-Gli. Moreover, the self-renewal of colon CSCs 
in vivo relies on Hh-Gli activity, which induces a robust EMT (Varnat et al., 2009). 
Extracellular matrix proteins. The extracellular matrix is a complex and dynamic structural 
network that is composed of structural proteins, proteoglycans, latent or active growth 
factors, and matricellular proteins. Cancer cell attachment and invasion of the ECM are 
crucial events leading to the initial disengagement from neighbor cells. Cancer cells can 
modify the composition of the adjacent stroma by secreting their own ECM proteins and by 
using the ECM proteins secreted by their neighbor stromal cells to create a permissive and 
supportive microenvironment for their survival, growth and invasion (Erkan et al., 2007; 
Ruan et al., 2009a). Type I collagen is highly expressed at the invasive front of human 
colorectal cancer. Type I collagen can decrease E-cadherin and β-catenin at cell-cell junctions 
and promote EMT on human colorectal carcinoma cells. Moreover, Type I collagen 
promotes a stem cell-like phenotype with an increased clonogenicity and expression of stem 
cell markers CD133 and Bmi-1 (Kirkland, 2009), indicating that Type I collagen may be 
involved in generating and maintaining human colorectal CSCs via EMT. 
Other microenvironment cues. In addition to TGF-β, Wnt, Notch, and Hh which play a 
critical role in inducing EMT and regulating the stemness of CSCs, several other autocrine 
and paracrine growth factors such as FGFs, IGF, HGF, EGF family members and PDGF, 
together with their receptors, are also involved in regulating the EMT program in 
development and tumorigenesis (Huber et al., 2005; Yang and Weinberg, 2008). These data 
suggest that these autocrine- or paracrine-mediated EMT may be associated with the 
maintenance of self-renewal in cancer stem-like cells. However, whether these secreted 
growth factors from tumor microenvironment and their receptors regulate the stemness  
of CSCs via EMT remains to be established. Interleukin-6 (IL-6) is a tumor 
microenvironment-derived extracellular signaling factor capable of inducing EMT 
(Sullivan et al., 2009). IL-6 is overexpressed in human breast tumors as well as breast 
cancer patient sera and is associated with a poor prognosis in breast cancer. IL-6 is 
secreted by cancer cells and/or stromal cells and induces MCF-7 breast cancer cells to 
undergo EMT characterized by impaired E-cadherin expression and induction of Vimentin, 
N-cadherin, Twist1 and Snai1 via the activation of STAT3 (Sullivan et al., 2009). Moreover, 
IL-6 can induce malignant properties in mammospheres from human ductal breast 
carcinoma and normal mammary gland (Sansone et al., 2009). Furthermore, oncogenic Ras 
induces the secretion of IL-6 in different cell types. Knockdown of IL-6, genetic ablation of 
IL-6, or treatment with a neutralizing IL-6 antibody can thwart Ras-mediated tumorigenesis 
(Ancrile et al., 2007). Recently, IL-6 signaling has also been shown to contribute to glioma 
malignancy by promoting glioma stem cell (GSC) growth and survival (Wang et al., 2009). 
GSCs preferentially express IL-6 receptors IL-6Rα and gp130. Knockdown IL-6Rα or IL-6 
ligand expression in GSCs significantly decreases growth and neurosphere formation but 
promotes apoptosis. Furthermore, STAT3 is a downstream mediator of pro-survival IL-6 
signals in GSCs. The levels of IL6 ligand and receptor are enhanced in gliomas and are 
associated with poor survival of glioma patients. Inhibiting IL-6Rα or IL-6 expression in 
GSCs promotes the survival of mice bearing intracranial human glioma xenografts (Wang et 
al., 2009). A recent report revealed that carcinoma-derived IL-6 is involved in activation of 
cancer-associated fibroblasts. Reciprocal activation of prostate cancer cells and cancer-
associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness 
(Giannoni et al., 2010). 
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2.2 EMT transcription factors in regulating stemness of CSCs 
E-cadherin is a central adhesion molecule located at cell-cell adhesion junctions and is 
essential for the formation and maintenance of the epithelial cell phenotype. Loss of  
E-cadherin is consistently observed at sites of EMT in embryonic development and 
tumorigenesis. Transcription factors such as Twist1, Snai1, Slug, ZEB1, ZEB2, FOXC2, KLF8 
and E47, can repress the E-cadherin promoter directly or indirectly (Kang and Massague, 
2004; Yang and Weinberg, 2008; Thiery et al., 2009). These transcription factors play critical 
roles in mediating type 1 EMT during embryogenesis and tissue morphogenesis; however, 
their aberrant activation of EMT developmental programs during tumorigenesis is 
considered a hallmark of disease progression and metastasis initiation. Among these 
developmental transcription factors, the Twist, Snai1 and ZEB family members are  
well-investigated in EMT and CSCs.  
Twist1 and Twist2. Twist proteins are highly conserved basic helix-loop-helix (bHLH) 
transcription factors that play an important role in embryogenesis and tumorigenesis. 
Twist1 and Twist2 are significantly over-expressed in various human solid tumors and are 
involved in tumor invasion and metastasis through their ability to promote EMT (Ansieau et 
al., 2008). Twist1 and Twist2 mediate the growth and commitment of human mesenchymal 
stromal/stem cells (MSC) (Isenmann et al., 2009). The levels of Twist1 and Twist2 are very 
high in freshly purified human bone marrow-derived MSCs but decrease following ex vivo 
expansion. Over-expression of Twist1 and Twist2 in human MSC cultures up-regulates the 
level of the MSC marker, STRO-1, and the early osteogenic transcription factors, Runx2 and 
Msx2. Therefore, Twist1 and Twist2 are potential mediators of MSC self-renewal and 
lineage commitment. Also these proteins may act to regulate critical transcription factors 
and osteo/chondrogenic inductive factors that are important in early events to determine 
cell fate decisions in human MSC populations (Isenmann et al., 2009). 
In a recent report, Mani et al. (2008) found that Twist1 can transform nontumorigenic, 
immortalized human mammary epithelial cells (HMLEs) into mesenchymal-like cells and 
dedifferentiate HER2/neu-infected HMLE (HMLEN) cells into CD44highCD24low cancer stem 
cells via EMT. Induction of EMT in nontumorigenic, immortalized mammary epithelial cells 
by ectopic expression of either Twist1 results in a population of stem-like cells. Moreover, 
the stem-like cells isolated from mouse and human normal and neoplastic mammary glands 
express markers associated with an EMT. Compare to the level in CD44low/CD24high cells, 
the expression of E-cadherin mRNA in stem-like CD44high/CD24low cells is strongly decreased 
(~150-fold), while the levels of mRNAs encoding mesenchymal markers and EMT-inducing 
transcription factors are significantly upregulated, specifically N-cadherin (~200-fold), 
Fibronectin (~60-fold), Twist1 (~198-fold), Snai1 (~9-fold), ZEB2 (~30-fold), and FOXC2  
(~16-fold). Furthermore, Twist1 can considerably increase the number of tumor-initiating 
cells in HER2/neu- or Ras-activated human mammary epithelial cells. The resulting 
populations that have undergone an EMT and display mesenchymal morphology and stem 
cell markers can efficiently form mammospheres, soft agar colonies, and tumors. This study 
provided direct support for a potential association between EMT and cancer stem-like cell 
phenotype. Vesuna et al. (2009) further demonstrated that Twist1 is directly involved in 
generating a breast CSC phenotype through down-regulation the expression of CD24. 
Twist2, like Twist1, overrides oncogene-induced premature senescence by promoting EMT 
in human epithelial cells (Ansieau et al., 2008). 
Twist2 has been shown to be overexpressed in several types of human cancers, but the 
expression pattern of Twist2 is different from that of Twist1 in these cancers, suggesting that 
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Twist1 and Twist2 may have overlapping but distinct roles in different set of tumors. Twist2 
is involved in p12CDK2-Ap1-induced EMT of hamster cheek pouch carcinoma-I cells (Tsuji et 
al., 2008). Our recent studies have suggested a role of Twist2 in regulating EMT and CSC 
stemness in human breast cancer progression (Fang et al., 2011). Twist2 is a potent inducer 
of EMT in human mammary epithelial cells and breast cancer cells. Ectopic expression of 
Twist2 in mammary epithelial cells and breast cancer cells increases the size and number of 
their CD44high/CD24low stem-like cell subpopulations, promotes the expression of stem cell 
markers and increases the self-renewal capabilities of stem-like cells. Moreover, exogenous 
expression of Twist2 leads to constitutive activation of STAT3 and down-regulation of  
E-cadherin (Fang et al., 2011). In addition, we also showed that the Twist2-driven EMT plays 
critical roles in ovarian cancer progression by promoting a cancer stem cell phenotype to 
augment tumor metastasis and therapeutic resistance (Mao et al., our unpublished data). 
Therefore, Twist2 may contribute to breast and ovarian cancer progression by activating the 
EMT program and enhancing the self-renewal of cancer stem-like cells. 
Snai1 and Slug. The Snail family is highly conserved zinc-finger transcription repressor and 
plays a pivotal role in embryonic development and tumorigenesis. Both Snai1 and Slug can 
be activated by the TGF-┚, Wnt, FGF, HGF and ER signaling pathways and Snai1 is 
specifically activated at the tumor-stroma interface. Snai1 has a critical role in EMT both 
during embryonic development and in tumor progression by inhibiting junction 
components such as E-cadherin, claudins, occludin and desmoplakin (Vincent, et al., 2009).  
Snai1-induced EMT accelerates tumor metastasis through enhanced invasion and the 
induction of multiple immunosuppression. Inhibition of Snai1-induced EMT can 
simultaneously suppress both tumor metastasis and immunosuppression in cancer patients 
(Kudo-Saito et al., 2009). Casas et al. (2010) reported that direct induction of Slug is essential 
for Twist1 to induce EMT and that Twist1 and Slug act together to promote EMT and tumor 
metastasis. In addition, Snai1 is a cofactor for Smad3/4 and these transcription factors form 
a transcriptional repressor complex to inhibit CAR, occluding and E-cadherin transcription 
during TGF-β-induced EMT in mammary epithelial cells (Vincent, et al., 2009). 
The well-established roles of Snai1 and Slug in EMT during embryogenesis and tumor 
progression indicate that they may also be involved in generating and maintaining the 
stemness of CSCs. Slug can protect hematopoietic progenitor cells from radiation-induced 
apoptosis in vivo (Inoue et al., 2002). A recent report demonstrated that Snai1 and Slug are 
critical for ovarian cancer cells to acquire stem cell characteristics, and upregulation of Snai1 
and Slug in ovarian cancer cells is associated with increased cell survival and acquisition of 
radioresistance and chemoresistance (Kurrey et al., 2009). Furthermore, Mani and colleagues 
(2008) found that Snai1 can generate cells with properties of stem cells via EMT induction 
like Twist1. When EMT is transiently induced in HMLEN cells through the ectopic 
expression of Snai1, the cells undergo an EMT and form more colonies in soft agar 
suspension culture but fail to form tumors more efficiently than untreated cells in vivo. 
However, constitutively expressing Snai1 in H-RasV12-infected HMLE (HMLER) cells 
augments the stem-like cell pool, mammosphere formation and tumorigenic property in 
vivo. This study also demonstrated that the long-term maintenance of the EMT/stem cell 
state may depend on continuous EMT-inducing signals (Mani et al., 2008).  
ZEB1 and ZEB2. The ZEB family proteins, ZEB1 and ZEB2, are implicated in the malignancy 
of various human tumors, and are important regulators in EMT and contribute to the drug 
resistance and stemness of CSCs (Peinado et al., 2007). Interestingly, ZEB1 can promote 
tumorigenesis and link the activation of EMT with the maintenance of CSC stemness by 
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repressing stemness-inhibiting microRNAs (miRNAs), which reinforces the direct relationship 
between EMT and the stemness of CSCs (Wellner et al., 2009). 
Bmi-1. Bmi-1, a member of the polycomb-repressive complex 1 (PRC1), is commonly 
deregulated in various tumors and plays an important role in maintaining self-renewal in 
normal and malignant human mammary stem cells (Dimri et al., 2002; Liu et al., 2005; Liu et 
al., 2006). Bmi-1 inhibits PTEN and induces EMT in human nasopharyngeal epithelial cells 
and is also involved in the regulation of self-renewal and differentiation of stem cells (Song 
et al., 2009b). A recent report showed that Bmi-1 can be regulated by Twist1 directly.  
Bmi-1-containing PRC directly represses E-cadherin expression. Bmi-1 and Twist1 are mutually 
essential to promote EMT and tumor-initiating capability of human head and neck 
squamous cell carcinoma cells (Yang et al., 2010). We also showed that Bmi-1 is involved in 
Twist2-induced EMT of mammary epithelial cells and breast cancer cells and cancer stem 
cell self-renewal (Fang et al., 2011). The current findings highlight the critical role of the 
polycomb group protens in regulating EMT and the stemness of CSCs. 
LBX1. Ladybird homeobox 1 (LBX1) is a well established homeobox regulator implicated in 
normal myogenesis and neurogenesis. Recent work has shown that LBX1 is over-expressed 
in the unfavorable ER/PR/HER2 triple-negative basal-like subtype of human breast cancer 
(Yu et al., 2009). Moreover, LBX1 is a potent activator of EMT and can regulate the 
expression of the known EMT inducers TGF-β2, Snai1, ZEB1 and ZEB2. LBX1 induces EMT, 
enhances cell migration, enlarges the CD44high/CD24low progenitor cell population in 
mammary epithelial cells, and cooperates with activated H-Ras to cause tumorigenesis and 
correlates with the basal subtype of human breast cancer (Yu et al., 2009). These results 
suggest that LBX1 is an important developmental regulator of oncogenic EMT and stemness 
of breast cancer stem cells and contributes to breast cancer aggressiveness. 
Six1. Six1, one of member of Six family of homeodomain proteins, is involved in the 
expansion of the precursor cell population during embryogenesis. In addition to the role of 
the Six family members in epithelial plasticity during muscle and kidney development, Six1 
is frequently overexpressed in various cancers and has been shown to play an important 
role in inducing features of EMT in both a mammary carcinoma cell line and in mammary 
tumors derived from mammary specific Six1 overexpressing transgenic mice (McCoy et al., 
2009; Micalizzi et al., 2009). Overexpression of Six1 in immortalized mammary epithelial 
cells induces malignant transformation and facilitates mammary carcinoma cells to undergo 
EMT and metastasis by increasing TGF-β signaling (Coletta et al., 2008; Micalizzi et al., 2009). 
Six1 also promotes the expansion of the stem/progenitor cell population in the mouse 
mammary gland and subsequent mammary tumor development via EMT (McCoy et al., 
2009. Therefore, over-expression of Six1 in breast cancer induce highly aggressive and 
invasive mammary tumors with EMT and cancer stem cell features. 
YB-1. Mammalian Y-box binding protein-1 (YB-1) is a member of the cold-shock domain 
(CSD) protein superfamily. Targeted disruption of YB-1 in mice causes severe developmental 
defects and embryonic lethality. YB-1 is involved in tumorigenesis and exhibits both  
pro-oncogenic role and tumor-suppressive functions by regulating gene expression through 
transcriptional and translational ways. YB-1 is over-expressed in ∼75% of human breast 
cancers and high YB-1 levels provoke remarkably diverse breast carcinomas through the 
induction of genetic instability (Bargou et al., 1997; Bergmann et al., 2005). Increased 
expression of YB-1 in premalignant mammary epithelial cells with elevated Ras-ERK 
signaling inhibits proliferation, disrupts mammary morphogenesis, and induces EMT and 
promotes invasive properties and cell dissemination (Evdokimova et al., 2009). YB-1 
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regulates EMT by directly promoting the cap-independent translation of mRNAs encoding 
Snai1, LEF-1, ZEB2 and other transcription factors involved in EMT and by suppressing  
cap-dependent translation of growth-related genes. Furthermore, premalignant MCF-10AT 
human mammary epithelial cells ectopically expressing YB-1 appear to obtain various stem 
cell properties such as low proliferation rates, upregulation of the stem cell markers p63, 
CD44, and downregulation of CD24 (Evdokimova et al., 2009). Therefore, MCF-10AT cells 
with ectopic upregulated YB-1 may acquire cancer stem cell phenotypes by inducing EMT. 
Hypoxia-inducible factors (HIFs). Intratumoral hypoxia occurs when tumor cells are 
located greater than the distance from functional blood vessels for adequate diffusion of 
oxygen as a result of rapid tumor cell growth and abnormal blood vessels. As one of the 
most pervasive microenvironmental stresses, hypoxia is now considered a common feature 
of solid tumors and promotes tumor angiogenesis, invasion and metastasis (Ruan et al., 
2009c). Hypoxia is also involved in regulating the stemness of stem cells. Low oxygen 
tensions promote the maintenance of pluripotency in hESCs and prevent differentiation. 
Interestingly, the subpopulation of brain tumor cells expressing a stem cell marker is 
enlarged by hypoxia in vitro. HIF-2α can regulate stem cell function and differentiation 
through the activation of Oct-4, which in turn contributes to the tumor promoting activity of 
HIF-2α (Covello et al., 2006). In glioblastomas, CSCs differentially respond to hypoxia with a 
distinct induction of HIF-2┙ (Li et al., 2009). HIF-2α-specific target genes such as Oct4, Glut1 
and SerpinB9 are expressed at significantly higher levels in GSCs compared to matched non-
stem cancer cells under hypoxic treatment. HIF-2┙ is also required for VEGF expression in 
GSCs, but not in non-stem cancer cells. Thus, HIF-2┙-mediated upregulation of these genes 
may provide CSCs with advantages in proliferation, survival, angiogenesis, metabolism, 
and escape from immune surveillance. Furthermore, targeting HIFs in GSCs inhibits  
self-renewal, proliferation and survival in vitro, and suppresses tumor initiation potential of 
GSCs in vivo (Li et al., 2009).  
Hypoxia can also induce EMTs in tumors through the upregulation of HIF-1┙, Snai1, 
Twist1, ZEB1, ZEB2, lysyl oxidase (LOX) and by activating Wnt and Notch pathways (Erler 
et al., 2006; Pouyssegur et al., 2006; Yang et al., 2008). Twist1 has a critical role in EMT and 
metastatic phenotypes induced by hypoxia or over-expression of HIF-1┙. In primary tumors 
of head and neck cancer patients, co-expression of HIF-1┙, Twist1 and Snai1 correlates with 
metastasis and a poor prognosis (Yang et al., 2008). Hypoxia can inhibit the expression of E-
cadherin via the activation of the LOX-Snai1 pathway to promote tumor invasion and 
metastasis, indicating that LOX may cooperate with Snai1 and Twist1 in hypoxia-mediated 
EMT and invasion (Pouyssegur et al., 2006; Yang et al., 2008). Jagged2 is upregulated in bone 
marrow stroma under hypoxia and promotes the growth of cancer stem-like cells by 
activating their Notch signaling. Hypoxia-induced Jagged2 activation in both tumor 
invasive front and normal bone stroma has a critical role in breast cancer metastasis and 
self-renewal of cancer stem-like cells (Xing et al., 2011). Therefore, high levels of HIFs in 
hypoxic tumor cells may promote cancer cells to acquire the properties of CSCs including 
self renewal and multi-potency by activating Oct4, c-Myc, Notch, Snai1 and other critical 
signaling pathways (Keith and Simon, 2007). Hypoxic microenvironment may be not only a 
critical niche favorable for expansion and stemness maintenance of CSCs in solid tumors, 
and also a breeding ground for generating CSCs from differentiated tumor cells by 
promoting EMT, and a critical microenvironmental condition that is associated with 
radioresistance, chemotherapy resistance and a poor clinical prognosis of solid tumors 
(Keith and Simon, 2007; Li et al., 2009). 
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In addition to Twist, Snail and ZEB family members and the transcription factors mentioned 
above, developmental transcription factors such as Goosecoid and FOXC2 have also 
emerged as key factors that regulate E-cadherin and promote EMT during embryonic 
development and tumorigenesis. Furthermore, these transcription factors may play a critical 
role in the stemness maintenance of CSCs via EMT. Goosecoid, a conserved transcription 
factor, is overexpressed in human breast tumors and can elicit an EMT to promote cell 
motility and significantly enhance the ability of breast cancer cells to form pulmonary 
metastases in mice (Hartwell et al. 2006). FOXC2 is associated with aggressive basal-like 
breast cancer and also confers stem cell properties on epithelial cells. FOXC2 specifically 
promotes mesenchymal differentiation via EMT and may serve as a critical mediator to 
orchestrate the mesenchymal component of the EMT program (Mani et al., 2007; Mani et al., 
2008). 
2.3 Other players of EMT in regulating stemness of CSCs 
microRNAs. microRNAs (miRNAs) are a newly discovered endogenous class of small  
non-coding RNAs of 18-25 nucleotide in length that modulate gene expression as negative 
regulators at the post-transcriptional level by specifically binding and cleaving target 
mRNAs or inhibiting their translation. Current reports demonstrated that the deregulation 
of miRNAs correlates with various human cancers and is involved in the initiation and 
progression of human cancers (Ruan et al., 2009b). Recently, miRNAs have also been 
identified as a new class of EMT regulators due to their regulation of EMT-inducing 
transcription factors, such as Twist1, Snai1, ZEB1 and ZEB2 (Ma and Weinberg, 2008).  
The miR-200 family of miRNAs (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) is 
both an important marker for epithelial cells and a powerful master regulator of EMT in 
embryonic development and tumorigenesis (Park et al., 2008). miR-200 suppresses the 
expression of ZEB1 and ZEB2 to favor an epithelial phenotype and inhibit EMT (Gregory et 
al., 2008; Korpal et al., 2008; Park et al., 2008). Moreover, let-7, miR-335, miR-205, miR-206, 
miR-126, miR-146a and miR-101 have also been reported as metastasis suppressors (Yu et al., 
2007; Gregory et al., 2008; Tavazoie et al., 2008; Varambally et al., 2008). Conversely, miRNAs 
such as miR-155, miR-10b, miR-21, miR-373 and miR-520c are involved in promoting tumor 
invasion and metastasis via regulating EMT (Ma et al., 2007; Huang et al., 2008; Kong et al., 
2008; Yan et al., 2008). For example, TGF-β stimulation of normal mammary epithelial cells 
elicits their increased expression of miR-155 via a Smad4-dependent pathway. Once 
expressed, miR-155 participates in EMT by inhibiting RhoA expression, leading to the 
dissolution of tight junctions (Kong et al., 2008). 
Recently, various miRNAs are also involved in regulating the stemness of embryonic  
stem cells, adult stem cells or CSCs. miRNAs are crucial for normal embryonic stem cell  
self-renewal and cellular differentiation (Marson et al., 2008). Recent reports demonstrated 
that a subset of the miR-290 cluster in the mouse and the miR-371 cluster in humans are 
direct regulators of the cell cycle in ES cells (Judson et al., 2009). A subset of the miR-290 
cluster, including miR-291-3p, miR-294 and miR-295, increased the efficiency of 
reprogramming by Oct4, Sox2 and Klf4, but not by these factors plus c-Myc (Judson et al., 
2009). A recent report demonstrated that the level of miR-145 is low in self-renewing hESCs 
but is much higher during differentiation. Furthermore, the pluripotency factors OCT4, 
SOX2, and KLF4 are direct targets of miR-145. miR-145 upregulation is sufficient to inhibit 
hESC self-renewal and induce lineage-restricted differentiation of hESCs (Xu et al., 2009).  
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Multiple members of the let-7 family of miRNAs are often inhibited in human cancers. A 
recent paper showed that let-7 is reduced in breast CSCs and can negatively regulate the 
stemness of breast CSCs and tumorigenesis by silencing H-Ras and HMGA2, regulators of 
self-renewal or differentiation of breast CSCs, respectively. Ectopic over-expression let-7 in 
breast CSCs reduces proliferation, mammosphere formation, and the proportion of 
undifferentiated cells in vitro. Also, in NOD/SCID mice, tumor formation and metastasis is 
reduced when let-7 is over-expressed (Yu et al., 2007). These findings indicate that a low 
level of let-7 is required to maintain CSCs, and let-7 may link EMT with CSCs. Interestingly, 
a recent paper demonstrated that miR-200c is differentially expressed between human 
breast CSCs and nontumorigenic cancer cells. miR-200c can target Bmi, a known regulator of 
stem cell self-renewal, and strongly inhibits the ability of normal breast stem cells to form 
mammary ducts and tumor formation driven by human breast CSCs (Shimono et al., 2009). 
Iliopoulos et al. (2010) demonstrated that downregulation of miR-200 lead to increased 
expression of Suz12, a subunit of the polycomb repressor complex 2, increased binding of 
Suz12 to the E-cadherin promoter, and upregulated H3-K27 trimethylation and polycomb-
mediated inhibition of E-cadhrein expression. The interactions between the miR-200 family 
are required for CSC formation. Xia et al. (2010) reported that miR-200a not only regulates 
EMT by targeting ZEB2 but also stem-like transition via differentially and specifically by  
┚-catenin signaling in nasopharyngeal carcinoma cells. This finding demonstrates for the 
first time the function of miR-200a in shifting nasopharyngeal carcinoma cell states via a 
reversible process coined as epithelial-mesenchymal to stem-like transition through 
differential and specific mechanisms. In addition, the stem cell factors, Sox2 and KLF4, are 
also targets of miR-200c. ZEB1 links EMT-activation with the maintenance of stemness of 
CSCs by suppressing stemness-inhibiting miRNAs such as miR-200c and miR-203 (Wellner 
et al., 2009). Induction of EMT can be controlled by miR-200 family whose abundance 
depends on the balance between Akt1 and Akt2 rather than on the overall activity of Akt 
(Iliopoulos et al., 2009). A recent report showed that EMT induction is epigenetically driven, 
initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing 
DNA methylation to sustain silencing of miR-200b, miR-200c, and miR-205 (Tellez et al., 
2011). These current data highlight the central role of miRNAs in regulating EMT and  
self-renewal and/or proliferation of normal and neoplastic stem cells. The miRNA 
signatures of CSCs likely represent a new layer of regulatory control over cell fate decisions 
of CSCs via EMT. 
p53. The tumor suppressor p53 is known to function as transcription factor. Recently, p53 
has been shown to exhibit a role in regulating both EMT and EMT-associated stem cell 
properties through transcriptional activation of miR-200c (Chang et al., 2011). Loss of p53 in 
human mammary epithelial cells decreases the expression of miR-200c and activates the 
EMT program, accompanied by an increased mammary stem cell population. Moreover, 
loss of p53 correlates with a down-regulated level of miR-200c, but an increased expression 
of EMT and stemness markers, and development of a high tumor grade in a cohort of breast 
tumors. Therefore, the p53-miR-200c pathway most likely accounts for regulating the EMT-
associated cancer stem cell population (Chang et al., 2011). 
3. Concluding remarks 
EMT is regarded as a critical step in tumor invasion and metastasis. During tumor metastasis, 
disseminated cancer cells from primary tumors are associated with a loss of epithelial 
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differentiation and the acquisition of a mesenchymal phenotype. Furthermore, these cancer 
cells appear to require the capability to self-renewal in order to spawn macroscopic 
metastases. The majority of disseminated cells are destroyed in the process of tumor 
metastasis; however, only a small number of cancer cells are able to survive and initiate the 
formation of micrometastases at the secondary sites, and even a smaller subpopulation of 
these micrometastases can develop into macrometastases (Bao et al., 2004). Current evidence 
supports that metastasis is a relatively inefficient process and the overwhelming majority of 
cells that shed from a primary tumor and disseminate to distant secondary sites lack the 
capability to self-renew and their ability to form macroscopic metastasis in the new 
microenvironment is compromised from the outset. The discovery that EMT generates cells 
with properties of self-renewing stem cells has linked EMT with both tumor metastasis and 
acquisition of stem-like cell properties, indicating that cancer cells undergo an EMT are 
capable of metastasizing through their acquired invasiveness and, following dissemination, 
through their acquired self-renewal potential, which enables them to spawn the large cell 
populations that constitute macroscopic metastases (Taube et al., 2010). 
EMT occurs in a variety of distinct physiological and pathological settings, including normal 
embryogenesis, tissue morphogenesis, tissue remodeling and repair and fibrosis, and cancer 
progression. A number of developmental signaling pathways have been shown to play a 
role in EMT such as TGF-┚, Wnt, Notch, Hh and other microenvironmental cues. These 
EMT-inducing signaling pathways promote the well-differentiated epithelial cells to convert 
into motile mesenchymal cells via the activation of multiple EMT transcription factors such 
as Twist1, Twist2, Snai1, Slug, ZEB1 and ZEB2. Each of these factors is capable, on its own, 
of inducing an EMT in various normal and cancer cell lines. However, the overlapping and 
unique contributions of each inducer to the EMT program have not been adequately 
explored. The critical roles of TGF-β, Wnt, Notch, Hh and other signaling pathways in 
promoting EMT and the stemness maintenance of stem cells adds to a growing body of 
evidence that cancer cells often reactivate latent developmental programs to regulate the 
multistep process in tumorigenesis. Therefore, the knowledge gained from the multifaceted 
players of EMT during development and from the acquisition of CSC traits with the EMT 
transdifferentiation program may provide useful information to uncover the roles of these 
EMT players in tumorigenesis and metastasis, and offer new avenues of therapeutic 
intervention with the potential to go beyond traditional anti-cancer approaches. 
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